Enliven Therapeutics, Inc. financial data

Symbol
ELVN on Nasdaq, IMRA on NYSE
Industry
Pharmaceutical Preparations
Location
6200 Lookout Road, Boulder, CO
State of incorporation
DE
Fiscal year end
December 31
Former names
IMARA Inc. (to 2/23/2023)
Latest financial report
10-K - Q4 2024 - Mar 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.59K % -17.5%
Debt-to-equity 6.56 % +19.5%
Return On Equity -29.2 % -9.83%
Return On Assets -27.4 % -8.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 49M shares +18.5%
Common Stock, Shares, Outstanding 48.9M shares +18.5%
Entity Public Float 684M USD +78.9%
Common Stock, Value, Issued 49K USD +19.5%
Weighted Average Number of Shares Outstanding, Basic 47.1M shares +32.4%
Weighted Average Number of Shares Outstanding, Diluted 47.1M shares +32.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 80.8M USD +25.1%
General and Administrative Expense 23.8M USD +25.4%
Operating Income (Loss) -105M USD -25.2%
Nonoperating Income (Expense) 15.5M USD +30%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -89M USD -24.4%
Earnings Per Share, Basic -1.89 USD/shares +5.97%
Earnings Per Share, Diluted -1.89 USD/shares +5.97%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 124M USD +23.9%
Marketable Securities, Current 189M USD +23.7%
Cash, Cash Equivalents, and Short-term Investments 313M USD +23.8%
Assets, Current 318M USD +19.5%
Property, Plant and Equipment, Net 458K USD -38.3%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 7.18M USD +75.4%
Assets 326M USD +19.8%
Accounts Payable, Current 1.34M USD +152%
Liabilities, Current 15.9M USD -38.5%
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 15.9M USD -38.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 55K USD -61%
Retained Earnings (Accumulated Deficit) -243M USD -57.6%
Stockholders' Equity Attributable to Parent 310M USD +26%
Liabilities and Equity 326M USD +19.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23.4M USD -12.1%
Net Cash Provided by (Used in) Financing Activities 90.3M USD -62%
Net Cash Provided by (Used in) Investing Activities -17.9M USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 48.9M shares +18.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 124M USD +23.9%
Deferred Tax Assets, Valuation Allowance 63.7M USD +48.9%
Deferred Tax Assets, Gross 63.7M USD +48.5%
Operating Lease, Liability 85K USD -79.4%
Depreciation 79K USD +17.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -89.1M USD -24.7%
Lessee, Operating Lease, Liability, to be Paid 0 USD -100%
Property, Plant and Equipment, Gross 1.38M USD -2.55%
Operating Lease, Liability, Current 85K USD -74.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 341K USD +3.65%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 0 USD -100%
Deferred Tax Assets, Operating Loss Carryforwards 24.6M USD +24.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 33.5M USD +4.08%
Additional Paid in Capital 553M USD +38.2%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 300K USD 0%
Share-based Payment Arrangement, Expense 20.2M USD +56.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%